Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Sermorelin for IGF-1 Elevation Research: Protocol Comparison

Mechanism Stimulates endogenous pituitary GH pulses via GHRH-R activation Exogenous GH bypasses pituitary, directly activates hepatic GH receptors Bypasses both pituitary and GH; direct IGF-1 receptor binding Sermorelin preserves physiological feedback loops;

This comparison does not assign a generated winner or score.

  • Mechanism
  • Stimulates endogenous pituitary GH pulses via GHRH-R activation
  • Exogenous GH bypasses pituitary, directly activates hepatic GH receptors
  • Bypasses both pituitary and GH; direct IGF-1 receptor binding
  • Sermorelin preserves physiological feedback loops; exogenous GH and IGF-1 override natural regulation, risking receptor desensitization
  • IGF-1 Elevation Timeline
  • 35–50% increase at 8–12 weeks; dose-dependent
  • 60–120% increase at 4–6 weeks; supraphysiological
  • 80–150% increase at 2–4 weeks; bypasses hepatic synthesis
  • Sermorelin timelines reflect natural synthesis kinetics; faster elevation with exogenous compounds but higher risk of tolerance
  • Pulsatility Preservation
  • Yes. Maintains 3–5 ultradian GH pulses/24h
  • No. Flattens rhythm into sustained elevation
  • N/A. No GH secretion involved
  • Preserved pulsatility critical for long-term studies; flat GH profiles trigger compensatory downregulation
  • Receptor Sensitivity
  • No tolerance development; negative feedback intact
  • Receptor downregulation by week 8–12 in most models
  • IGF-1 receptor internalization with chronic supraphysiological dosing
  • Sermorelin avoids tolerance; exogenous pathways risk invalidating results in protocols >12 weeks
  • Reconstitution Stability
  • 28 days at 2–8°C post-reconstitution; lyophilized stable 36 months at −20°C
  • 14–21 days refrigerated; highly sensitive to temperature excursions
  • 7–10 days refrigerated; oxidation-prone without stabilizers
  • Sermorelin offers widest study window; GH and IGF-1 require more frequent batch preparation
  • Research Cost per 12-Week Protocol
  • $180–$320 depending on dose and purity grade
  • $800–$1,500 for pharmaceutical-grade recombinant GH
  • $400–$900 for research-grade IGF-1
  • Sermorelin provides best cost-to-mechanistic-insight ratio for pituitary function studies